Selective targeting of tumor vasculature using radiolabelled antibody molecules

A method of treating a tumor, comprising administering to a patient in need thereof an antibody that binds human ED-B, wherein the antibody is labeled with an isotope which is 76Br, 77Br, 123I, 124I, 131I or 211At and comprises an antigen-binding site that comprises an antibody VH domain and an antibody VL domain, wherein the antibody VH domain comprises an L19 VH domain or a VH domain comprising a VH CDR1, a VH CDR2 and a VH CDR3,

• wherein
• the VH CDR3 is the L19 VH CDR3 of SEQ ID NO. 3,
• the VH CDR1 is optionally L19 VH CDR1 of SEQ ID NO. 1, and
• the VH CDR2 is optionally L19 VH CDR2 of SEQ ID NO. 2;
• and wherein
• the antibody VL domain optionally comprises an L19 VL domain or a VL domain comprising a VL CDR1, a VL CDR2 and a VL CDR3,
• wherein
• the VL CDR3 is the L19 VL CDR3 of SEQ ID NO. 6,
• the VL CDR1 is optionally L19 VL CDR1 of SEQ ID NO. 4, and
• the VL CDR2 is optionally L19 VL CDR2 of SEQ ID NO. 5;
• the L19 VH domain comprises SEQ ID NO:
• 14 and L19 VL domain comprises SEQ ID NO:
• 15;
• wherein the antibody is in a format which comprises a mini-immunoglobulin comprising said antibody VH domain and antibody VL domain fused to εS2-CH4 and dimerized, or comprises a whole IgG1 antibody molecule.

A method of treating a lesion of pathological angiogenesis, comprising tumor, comprising administering to a patient in need thereof an antibody that binds human ED-B, wherein the antibody is labeled with an isotope which is 76Br, 77Br, 123I, 124I, 131I or 211At and comprises an antigen-binding site that comprises an antibody VH domain and an antibody VL domain, wherein the antibody VH domain comprises an L19 VH domain or a VH domain comprising a VH CDR1, a VH CDR2 and a VH CDR3,

• wherein
• the VH CDR3 is the L19 VH CDR3 of SEQ ID NO. 3,
• the VH CDR1 is optionally L19 VH CDR1 of SEQ ID NO. 1, and the VH CDR2 is optionally L19 VH CDR2 of SEQ ID NO. 2;
• and wherein
• the antibody VL domain optionally comprises an L19 VL domain or a VL domain comprising a VL CDR1, a VL CDR2 and a VL CDR3,
• wherein
• the VL CDR3 is the L19 VL CDR3 of SEQ ID NO. 6,
• the VL CDR1 is optionally L19 VL CDR1 of SEQ ID NO. 4, and
• the VL CDR2 is optionally L19 VL CDR2 of SEQ ID NO. 5;
• the L19 VH domain comprises SEQ ID NO:
• 14 and L19 VL domain comprises SEQ ID NO:
• 15;
• wherein the antibody is in a format which comprises a mini-immunoglobulin comprising said antibody VH domain and antibody VL domain fused to εS2-CH4 and dimerized, or comprises a whole IgG1 antibody molecule.